



CERTIFICATE OF ANALYSIS

Product Description: V-PLEX® A β Peptide Panel 1 (6E10) Kit**Lot Number:** K0082664**Expiration Date:** 30 SEP 2026**Catalog Number:** K15200-Series, K150SI-Series**Lot-Specific Components:**

Description	Lot Number	Storage Temperature	Expiration Date
Anti-A β 6E10 Antibody	D0082394	2-8°C	31 MAY 2028
Anti-A β 6E10 Antibody	D0082394	2-8°C	31 MAY 2028
Anti-A β 6E10 Antibody	D0082394	2-8°C	31 MAY 2028
A β Peptide Panel 1 (6E10) 96-Well 4-Spot SECTOR Plate	Z0057558	2-8°C	31 AUG 2027
Diluent 100	Y0270344	2-8°C	30 APR 2027
Diluent 35	M0350039	2-8°C	30 JUN 2027
A β 1-42 Peptide (6E10)	A0080409	$\leq -70^{\circ}\text{C}$	28 FEB 2027
A β 1-38 Peptide (6E10)	A0080390	$\leq -70^{\circ}\text{C}$	30 SEP 2026
A β 1-40 Peptide (6E10)	A0080408	$\leq -70^{\circ}\text{C}$	31 MAR 2027
A β 40 Blocker	R0010910	2-8°C	30 APR 2027

Additional components may be provided to execute the assay. Additional components are not lot-specific.

Precision, Accuracy, and Sensitivity Specifications:

		Calibrator		Neurodegeneration Control 1 (6E10)		Neurodegeneration Control 2 (6E10)		Neurodegeneration Control 3 (6E10)	
Spot	Name	Recovery	CV	Recovery	CV	Recovery	CV	Recovery	CV
1	A β 40	80% - 120%	< 20%	75% - 125%	< 20%	75% - 125%	< 20%	75% - 125%	< 20%
2	A β 38	80% - 120%	< 20%	75% - 125%	< 20%	75% - 125%	< 20%	75% - 125%	< 20%
4	A β 42	80% - 120%	< 20%	75% - 125%	< 20%	75% - 125%	< 20%	75% - 125%	< 20%

		LLOQ			ULOQ		
Spot	Name	Value	Recovery	CV	Value	Recovery	CV
1	A β 40	50.0	80% - 120%	< 20%	7000	80% - 120%	< 20%
2	A β 38	60.0	80% - 120%	< 20%	8480	80% - 120%	< 20%
4	A β 42	3.13	75% - 125%	< 20%	1270	80% - 120%	< 20%

Non-Specific Binding Specifications:

Spot	Name	A β 40	A β 38	A β 42
1	A β 40	NA	< 1.0%	< 1.0%
2	A β 38	< 1.0%	NA	< 1.0%
4	A β 42	< 1.0%	< 1.0%	NA



CERTIFICATE OF ANALYSIS

Stock Concentration of Calibrator:

Spot	Name	Conc.	Units
1	A β 40	580000	pg/mL
2	A β 38	500000	pg/mL
4	A β 42	72800	pg/mL

Dilution to top of Curve: 40X

This product is intended for Research Use Only. Not for use in Diagnostic Procedures.

	Name	Function	Signature	Date
Review/Approval	Karen Hamilla	Quality		18 APR 2025